MAPT and Alzheimer disease: A detailed assessment of neuropsychiatric symptoms within each cluster is also essential, especially since these symptoms often manifest as MBI that predicts cognitive decline and correlates with biomarkers of AD, such as plasma phosphorylated tau, neurofilament light chain (NfL), and amyloid profiles, underscoring their biological significance [7].